细胞周期检测点激酶与肺癌耐药研究进展  

Cell Cycle Checkpoint Kinase and Drug Resistance of Lung Cancer

作　　者：柯芷茵 梁爱玲 刘勇军 Zhiyin KE;Ailing LIANG;Yongjun LIU(Medical Molecular Diagnostics Key Laboratory of Guangdong,Dongguan 523808,China;Department of Biochemistry and Molecular Biology Guangdong Medical University,Dongguan 523808,China;Department of Clinical Laboratory Biochemistry in Guangdong Medical University,Dongguan 523808,China)

机构地区：[1]广东省医学分子诊断重点实验室,东莞523808 [2]广东医科大学基础医学院生物化学与分子生物学教研室,东莞523808 [3]广东医科大学医学技术学院临床生物化学教研室,东莞523808

出　　处：《中国肺癌杂志》2021年第4期265-270,共6页Chinese Journal of Lung Cancer

摘　　要：肺癌是最常见的诊断癌症和癌症死亡的主要原因。虽然化疗、放疗、靶向治疗等治疗手段取得了重大进展,但获得性耐药的出现阻碍了临床治疗的疗效。研究表明肿瘤是一类细胞周期调控机制破坏的疾病,其中细胞周期检测点激酶(checkpoint kinase,Chk)发挥着核心的作用,而Chk1和Chk2是检测点中非常重要的蛋白激酶。近年来发现,调控Chk1和Chk2对肺癌的临床治疗和耐药机制有十分重要的意义。本文就细胞周期检测点激酶与肺癌耐药机制进行综述,阐述有效的肺癌治疗靶点和方法。Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death.Although great progress has been made in chemotherapy,radiotherapy and targeted therapy,the emergence of acquired drug resistance hinders the efficacy of clinical treatment.Studies have shown that tumor is a class of diseases with damaged cell cycle regulation mechanism,in which checkpoint kinase(Chk)plays a core role,Chk1 and Chk2 are very important protein kinases in the checkpoint.In recent years,it has been found that the regulation of Chk1 and Chk2 plays an important role in the clinical treatment and drug resistance mechanism of lung cancer.This article reviews the mechanism of cell cycle checkpoint kinase and drug resistance of lung cancer,and expounds the effective therapeutic targets and methods of lung cancer.

关 键 词：细胞周期检测点激酶 肺肿瘤 耐药 

分 类 号：R734.2[医药卫生—肿瘤]